Dostarlimab Delivers Impressive Results in Rectal Cancer, But More ...
2024年6月24日 · Dostarlimab-gxly (Jemperli), a PD-1 inhibitor and immunotherapy drug, has shown remarkable potential in the treatment of patients with colorectal cancer, specifically in …
CAPOX Regimen Appears Noninferior to FOLFOX in Colorectal …
2023年10月8日 · The treatment landscape for patients with resected stage III colon cancer has undergone a significant change, following publication of an International Development and …
Top 10 Breast Cancer Breakthroughs in 2024 - targetedonc.com
2024年12月23日 · In 2024, several significant advancements in breast oncology were covered by Targeted Oncology TM. Here are the top 10 developments from the year: FDA Approval of …
Perioperative Pembrolizumab Betters Survival in Stage III/IV Head …
2024年10月8日 · Perioperative pembrolizumab (Keytruda) led to improved event-free survival (EFS) in patients with stage III or IVA, resected head and neck squamous cell carcinoma …
TNBC Vaccine Shows Promising Safety, Immune Response in …
2024年11月22日 · An investigational breast cancer vaccine for triple-negative breast cancer (TNBC) showed encouraging results, with over 70% of patients exhibiting protocol-defined …
Revumenib for NPM1-Mutant AML Succeeds in Pivotal Trial
2024年11月12日 · In the phase 2 AUGMENT-101 trial, revumenib met its primary end point by achieving a complete remission or complete remission with partial blood count recovery in …
Advancements in Follicular Lymphoma Treatment With Targeted …
2024年11月14日 · The treatment options for follicular lymphoma (FL) are rapidly advancing, driven by the development of new, promising therapies. At the 42nd Annual Chemotherapy …
T-DXd in ER+/HER2-Low Breast Cancer: Insights From DESTINY …
2024年12月11日 · Aditya Bardia, MD, MPH, FASCO, professor, department of medicine, division of hematology/oncology, director of translational research integration, UCLA Health Jonsson …
Palbociclib Combo Shows Benefit to PFS in HR+, HER2+ Breast …
2024年12月12日 · A statistically significant and clinically meaningful median progression-free survival (PFS) improvement was demonstrated with palbociclib (Ibrance) plus standard-of-care …
Recurrence-Free Survival in GIST at 90% With Long-Term Imatinib
2017年8月22日 · Chandrajit P. Raut, MD. Patients with intermediate- or high-risk gastrointestinal stromal tumors (GIST) were less likely to experience recurrence after 5 years of treatment with …